Marzia Capelletti

14.4k total citations · 3 hit papers
66 papers, 5.2k citations indexed

About

Marzia Capelletti is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marzia Capelletti has authored 66 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 29 papers in Molecular Biology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marzia Capelletti's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (13 papers) and HER2/EGFR in Cancer Research (10 papers). Marzia Capelletti is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (13 papers) and HER2/EGFR in Cancer Research (10 papers). Marzia Capelletti collaborates with scholars based in United States, Italy and France. Marzia Capelletti's co-authors include Pasi A. Jänne, Dalia Ercan, Nathanael S. Gray, Michael J. Eck, Cai‐Hong Yun, Kwok‐Kin Wong, Andrea Ardizzoni, Tauro Maria Neri, James G. Christensen and Roberta Camisa and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Marzia Capelletti

66 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

2009 785 citations Wenjun Zhou, Dalia Ercan et al. Nature profile →
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer

2008 745 citations Antonino Musolino, Nadia Naldi et al. Journal of Clinical Oncology profile →
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

2010 604 citations James E. Butrynski, David R. D’Adamo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marzia Capelletti United States	27	2.9k	2.6k	2.5k	816	642	66	5.2k
Margaret Dugan United States	29	2.5k 0.9×	1.3k 0.5×	1.9k 0.8×	1.4k 1.7×	351 0.5×	71	6.2k
Juliann Chmielecki United States	40	3.6k 1.2×	4.1k 1.6×	2.8k 1.1×	1.8k 2.2×	240 0.4×	116	7.2k
Herlinde Dumez Belgium	35	1.7k 0.6×	2.3k 0.9×	1.5k 0.6×	454 0.6×	323 0.5×	145	4.8k
Barbara J. Gitlitz United States	37	1.9k 0.6×	2.8k 1.1×	2.2k 0.9×	855 1.0×	282 0.4×	118	4.5k
Akihiko Kawahara Japan	37	3.1k 1.1×	2.0k 0.8×	1.7k 0.7×	919 1.1×	277 0.4×	188	5.1k
Sarah Minner Germany	35	1.1k 0.4×	1.9k 0.7×	2.0k 0.8×	1.2k 1.4×	287 0.4×	127	4.2k
Todd M. Bauer United States	50	5.4k 1.9×	4.2k 1.6×	2.9k 1.2×	1.5k 1.9×	513 0.8×	264	8.6k
Alexa B. Schrock United States	41	3.7k 1.3×	3.1k 1.2×	1.7k 0.7×	1.8k 2.1×	181 0.3×	259	6.0k
David M. Peereboom United States	39	1.7k 0.6×	1.7k 0.7×	1.3k 0.5×	613 0.8×	365 0.6×	198	4.8k
Youngchul Song United States	13	3.0k 1.0×	2.7k 1.0×	3.0k 1.2×	908 1.1×	510 0.8×	18	5.5k

Countries citing papers authored by Marzia Capelletti

Since Specialization

Citations

This map shows the geographic impact of Marzia Capelletti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marzia Capelletti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marzia Capelletti more than expected).

Fields of papers citing papers by Marzia Capelletti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marzia Capelletti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marzia Capelletti. The network helps show where Marzia Capelletti may publish in the future.

Co-authorship network of co-authors of Marzia Capelletti

This figure shows the co-authorship network connecting the top 25 collaborators of Marzia Capelletti. A scholar is included among the top collaborators of Marzia Capelletti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marzia Capelletti. Marzia Capelletti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsukamoto, Shokichi, Marianne Bengtson Løvendorf, Jihye Park, et al.. (2018). Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia. 32(8). 1739–1750. 33 indexed citations

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

Redig, Amanda J., Marzia Capelletti, Suzanne E. Dahlberg, et al.. (2016). Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer. Clinical Cancer Research. 22(13). 3148–3156. 53 indexed citations

Chong, Curtis R., Magda Bahcall, Marzia Capelletti, et al.. (2016). Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research. 23(1). 204–213. 67 indexed citations

Xu, Chunxiao, Sharmeen Uddin, Marzia Capelletti, et al.. (2015). Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer. Cancer Discovery. 5(9). 960–971. 159 indexed citations

Soucheray, Margaret, Marzia Capelletti, Yanan Kuang, et al.. (2015). Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research. 75(20). 4372–4383. 103 indexed citations

Ercan, Dalia, Hwan Geun Choi, Cai‐Hong Yun, et al.. (2015). EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research. 21(17). 3913–3923. 291 indexed citations

Tanizaki, Junko, Dalia Ercan, Marzia Capelletti, et al.. (2015). Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Research. 75(15). 3139–3146. 30 indexed citations

Wilson, Frederick H., Cory M. Johannessen, Federica Piccioni, et al.. (2015). A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell. 27(3). 397–408. 130 indexed citations

10.

Capelletti, Marzia, Michael Dodge, Dalia Ercan, et al.. (2014). Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma. Clinical Cancer Research. 20(24). 6551–6558. 79 indexed citations

11.

Cortot, Alexis B., Claire E. Repellin, Takeshi Shimamura, et al.. (2012). Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research. 73(2). 834–843. 163 indexed citations

12.

He, Mai, Marzia Capelletti, Khédoudja Nafa, et al.. (2011). EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma. Clinical Cancer Research. 18(6). 1790–1797. 109 indexed citations

13.

Sasaki, Takaaki, Katsuhiro Okuda, Wei Zheng, et al.. (2010). The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research. 70(24). 10038–10043. 254 indexed citations

14.

Ercan, Dalia, Kreshnik Zejnullahu, Kimio Yonesaka, et al.. (2010). Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 29(16). 2346–2356. 181 indexed citations

15.

Butrynski, James E., David R. D’Adamo, Jason L. Hornick, et al.. (2010). Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine. 363(18). 1727–1733. 604 indexed citations breakdown →

16.

Zhou, Wenjun, Dalia Ercan, Liang Chen, et al.. (2009). Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 462(7276). 1070–1074. 785 indexed citations breakdown →

17.

Tiseo, Marcello, Giulio Rossi, Marzia Capelletti, et al.. (2009). Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer. 67(3). 355–360. 61 indexed citations

18.

Musolino, Antonino, Nadia Naldi, Beatrice Bortesi, et al.. (2008). Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 26(11). 1789–1796. 745 indexed citations breakdown →

19.

Musolino, Antonino, Maria Angela Bella, Beatrice Bortesi, et al.. (2007). BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. The Breast. 16(3). 280–292. 101 indexed citations

20.

Musolino, Antonino, Maria Michiara, Maria Angela Bella, et al.. (2005). Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. Tumori Journal. 91(6). 505–512. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact